ZBH - Stryker Still A Med-Tech King But There Are Challengers To The Throne
- Stronger procedure volumes and normalizing hospital capex should drive stronger revenue for Stryker in 2021, with a long-term path to strong mid-single-digit growth.
- Stryker's knee business had a rare quarter of underperformance, and Zimmer's much-improved business is a threat to watch, but Mako-driven growth is still a positive driver.
- With more time to plan for the Wright Medical integration, sales disruption should be lower than usual, and an enhanced extremities business is a key growth driver for Stryker.
- Today's price seems to offer long-term mid-single-digit appreciation potential, but this is certainly a name to consider if there's a broader selloff.
For further details see:
Stryker Still A Med-Tech King, But There Are Challengers To The Throne